This report titled angiotensin converting enzyme (ACE) inhibitors market studies various drug type, application type and geographical scenario. According to Cleveland Clinic, an ACE inhibitor is a type of vasodilator that dilates the blood vessels to improve the amount of blood the heart pumps in patients suffering from high blood pressure. An ACE inhibitor also increases blood flow, which will help decrease the amount of work the heart has to do and may also decrease your blood pressure. The renin-angiotensin-aldos-terone system (RAAS) plays a key physiologic role in the regulation of blood pressure in the human body. In RAAS, ACE plays an important role in the production of angiotensin II where it facilitates the conversion of the biologically inactive angiotensin I to angiotensin II. Angiotensin II increases blood pressure by its action as a potent vasoconstrictor and stimulates the production of aldosterone, which promotes sodium and water retention in the body. Therefore, a substance that inhibits ACE will decrease the production of angiotensin II and reduce blood pressure. According to World Health Organization (WHO), high blood pressure is one of the most important causes of premature death worldwide killing nearly 9.4 million people every year globally, and the problem is growing. The WHO data further suggested that the prevalence of raised blood pressure was highest in the African Region (46%) and lowest in the Region of the Americas (35%). In the South-East Asia Region, 36% of adults have hypertension. Thus, rising prevalence of hypertension and diabetes, and high public awareness related with early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitors market.
The major key players profiled in the ACE inhibitors market are on the basis of various characteristics such as business description, financial health and budget allocation, product portfolio, and news coverage. The key players profiled in this report are Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Jhonson and Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.
In base year 2021, hypertension and diabetes applications collectively accounted for the largest market share and are expected to maintain its domination throughout the forecast period 2023 – 2030. The rising prevalence of hypertension and diabetes, and high public awareness related with early diagnosis and management of these disorders are the key factors assisting the overall ACE inhibitors market. According to World Health Organization (WHO), globally cardiovascular disease accounts for approximately 17 million deaths a year, nearly one third of the total. Of these, complications of hypertension account for 9.4 million deaths worldwide every year. The global economic burden of increased blood pressure was estimated to consume US$370 billion worldwide and 10% of healthcare expenditures. ACE inhibitors also play vital role in treatment of chronic kidney diseases and other cardiovascular diseases such as heart failure and myocardial infarction. Chronic kidney disorders application segment was observed as the fastest moving segment in overall ACE inhibitors market throughout the forecast period 2023 – 2030.
Angiotensin converting enzyme (ACE) inhibitors are high blood pressure drugs that widen or dilate the blood vessels to improve the amount of blood the heart pumps and to lower blood pressure. Overall, about half of people (50%) with high blood pressure do not have their condition under control, according to recent data from the Centers for Disease Control and Prevention and the National Health and Nutrition Examination Survey (NHANES). According to British Hypertension Society, these drugs inhibit the activity of ACE to prevent formation of the active octapeptide, angiotensin II, from the inactive decapeptide, angiotensin I. This process mainly occurs in blood and tissues including kidney, heart, blood vessels, adrenal gland and brain. Angiotensin II is a potent vasoconstrictor that promotes aldosterone release and facilitates sympathetic activity along with other potentially harmful effects on the cardiovascular system. Drop in blood pressure secondary to vasodilatation following ACE inhibition is greatest when the renin-angiotensin system is stimulated but ACE inhibitors also lower blood pressure when there is normal or low activity of the renin-angiotensin system. Market experts suggest that lisinopril and ramipril are most popular than comparable drugs due to dosage convenience, good insurance coverage, and higher efficiency along with low side-effects.
In base year 2021, North America was observed as the largest and most potential regional market for ACE inhibitors. North America constitutes regional markets of U.S. and Canada, the rising prevalence of hypertension and kidney disorders is one of the key factors that assists the ACE inhibitors market in this region. The developed healthcare infrastructure, high public awareness related to lifestyle diseases and treatment, and rising research and development activities related to management of lifestyle diseases are the key factors assisting the growth of North America ACE inhibitors market. Asia Pacific is expected to be the fastest growing regional markets for ACE inhibitors market throughout the forecast period. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centered in China, India and Japan. Several factors such as rising prevalence of hypertension and kidney disorders along with high public awareness related to diagnosis of lifestyle diseases is assisting the growth of Asia Pacific market. The other factors assisting the growth of ACE inhibitors market are aging population, as well as other risk factors such as obesity, physical inactivity, and alcohol consumption in this region.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Angiotensin Converting Enzyme (ACE) Inhibitors market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Drug Type
| |
Application
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
